Almstead Neil Gregory 4

What Happened
Neil Gregory Almstead, Chief Technical Operations Officer at PTC Therapeutics (PTCT), sold a total of 3,121 shares on February 18, 2026 in two open-market/private-sale transactions at $69.36 per share. The transactions were: 3,056 shares for $211,964 and 65 shares for $4,508, for a combined value of about $216,472. These sales were automatic "sell-to-cover" transactions to satisfy tax-withholding obligations tied to vested restricted stock units (RSUs), not voluntary discretionary sales.

Key Details

• Transaction date: 2026-02-18; Price: $69.36 per share.
• Shares sold: 3,056 + 65 = 3,121 shares; Gross proceeds ≈ $216,472.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnotes: F1 and F2 state these were automatic sell-to-cover elections tied to vesting of RSUs from Feb 15, 2024 grants (F1 covers vesting of 4,750 RSUs from a 19,000-RSU grant and 3,000 RSUs from a 6,000-RSU grant; F2 covers 217 RSUs from an 870-RSU grant).
• Filing timeliness: Report filed 2026-02-20 for transactions on 2026-02-18 — filed within the typical two-business-day Form 4 window.

Context
Sell-to-cover transactions are routine—they automatically liquidate a portion of newly vested RSUs to cover tax withholding and do not necessarily signal management sentiment about the stock. The filing notes the sales were tied to RSU vesting (i.e., not open-market, discretionary sales) and were executed pursuant to irrevocable sell-to-cover elections made when the grants were accepted.